YARROW BIOSCIENCE, INC. Research and Development Expense
YARROW BIOSCIENCE, INC. (YARW) reported Research and Development Expense of $788.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- YARROW BIOSCIENCE, INC. research and development expense for the quarter ending 2026-06-30 was $788.00K, a 83.86% decline year-over-year.
- YARROW BIOSCIENCE, INC. research and development expense for the quarter ending 2026-03-31 was $817.00K, a 86.66% decline year-over-year.
- YARROW BIOSCIENCE, INC. research and development expense for the quarter ending 2025-06-30 was $4.88M, a 33.19% decline year-over-year.
- YARROW BIOSCIENCE, INC. research and development expense for the quarter ending 2025-03-31 was $6.12M, a 65.16% increase year-over-year.
- YARROW BIOSCIENCE, INC. research and development expense for fiscal 2023 was $16.31M, a 11.30% decline from fiscal 2022.
- YARROW BIOSCIENCE, INC. research and development expense for fiscal 2022 was $18.39M, a 5.93% decline from fiscal 2021.
- YARROW BIOSCIENCE, INC. research and development expense for fiscal 2021 was $19.54M, a 55.11% decline from fiscal 2020.
- YARROW BIOSCIENCE, INC. research and development expense for fiscal 2020 was $43.53M, a 14.98% decline from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $788.00K 10-Q · filed 2026-08-13 | $1.60M 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | $817.00K S-4/A · filed 2026-06-03 | |||||||
| 2025-12-31 | $19.24M S-4/A · filed 2026-06-03 | |||||||
| 2025-06-30 | $4.88M 10-Q · filed 2026-08-13 | $11.00M 10-Q · filed 2026-08-13 | $20.69M derived: sum of 3 quarters · filed 2026-08-13 | $30.94M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $6.12M S-4/A · filed 2026-06-03 | $15.81M derived: sum of 2 quarters · filed 2026-06-03 | $26.06M derived: sum of 3 quarters · filed 2026-06-03 | $33.36M derived: sum of 4 quarters · filed 2026-06-03 | ||||
| 2024-12-31 | $9.68M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-06-03 | $19.93M derived: sum of 2 quarters · filed 2026-06-03 | $27.24M derived: sum of 3 quarters · filed 2026-06-03 | $30.95M S-4/A · filed 2026-06-03 | ||||
| 2024-09-30 | $10.25M 10-Q · filed 2024-11-07 | $17.55M derived: sum of 2 quarters · filed 2025-08-14 | $21.26M 10-Q · filed 2024-11-07 | $24.29M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-06-30 | $7.31M 10-Q · filed 2025-08-14 | $11.01M 10-Q · filed 2025-08-14 | $14.04M derived: sum of 3 quarters · filed 2025-08-14 | $17.36M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $3.71M 10-Q · filed 2025-05-08 | $6.73M derived: sum of 2 quarters · filed 2025-05-08 | $10.05M derived: sum of 3 quarters · filed 2025-05-08 | $17.28M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $6.34M derived: sum of 2 quarters · filed 2025-03-06 | $13.57M derived: sum of 3 quarters · filed 2025-03-06 | $16.31M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $3.32M 10-Q · filed 2024-11-07 | $10.55M derived: sum of 2 quarters · filed 2024-11-07 | $13.28M 10-Q · filed 2024-11-07 | $17.56M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $7.23M 10-Q · filed 2024-08-14 | $9.97M 10-Q · filed 2024-08-14 | $14.25M derived: sum of 3 quarters · filed 2024-08-14 | $19.79M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.73M 10-Q · filed 2024-05-09 | $7.01M derived: sum of 2 quarters · filed 2024-05-09 | $12.56M derived: sum of 3 quarters · filed 2024-05-09 | $16.67M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $9.82M derived: sum of 2 quarters · filed 2024-03-01 | $13.93M derived: sum of 3 quarters · filed 2024-03-01 | $18.39M 10-K · filed 2024-03-01 | ||||
| 2022-09-30 | $5.55M 10-Q · filed 2023-11-13 | $9.65M derived: sum of 2 quarters · filed 2023-11-13 | $14.11M 10-Q · filed 2023-11-13 | $18.43M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $4.11M 10-Q · filed 2023-08-14 | $8.56M 10-Q · filed 2023-08-14 | $12.88M derived: sum of 3 quarters · filed 2023-08-14 | $18.80M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $4.45M 10-Q · filed 2023-05-11 | $8.78M derived: sum of 2 quarters · filed 2023-05-11 | $14.69M derived: sum of 3 quarters · filed 2023-05-11 | $19.74M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $10.24M derived: sum of 2 quarters · filed 2023-03-14 | $15.29M derived: sum of 3 quarters · filed 2023-03-14 | $19.54M 10-K · filed 2023-03-14 | $24.96M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $5.92M 10-Q · filed 2022-11-14 | $6.98M 10-Q · filed 2021-11-10 | $10.96M derived: sum of 2 quarters · filed 2022-11-14 | $15.22M 10-Q · filed 2022-11-14 | $19.72M 10-Q · filed 2021-11-10 | $23.06M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $5.05M 10-Q · filed 2022-08-12 | $6.41M 10-Q · filed 2021-08-12 | $9.30M 10-Q · filed 2022-08-12 | $12.74M 10-Q · filed 2021-08-12 | $17.14M derived: sum of 3 quarters · filed 2022-08-12 | $23.76M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $4.25M 10-Q · filed 2022-05-12 | $6.33M 10-Q · filed 2021-05-06 | $12.09M derived: sum of 2 quarters · filed 2022-05-12 | $18.72M derived: sum of 3 quarters · filed 2022-05-12 | $31.84M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $7.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $14.46M derived: sum of 2 quarters · filed 2022-03-17 | $27.58M derived: sum of 3 quarters · filed 2022-03-17 | $43.53M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $6.62M 10-Q · filed 2021-11-10 | $19.74M derived: sum of 2 quarters · filed 2021-11-10 | $35.70M 10-Q · filed 2021-11-10 | $51.04M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $13.12M 10-Q · filed 2021-08-12 | $29.07M 10-Q · filed 2021-08-12 | $44.42M derived: sum of 3 quarters · filed 2021-08-12 | $56.87M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $15.95M 10-Q · filed 2021-05-06 | $31.30M derived: sum of 2 quarters · filed 2021-05-06 | $43.75M derived: sum of 3 quarters · filed 2021-05-06 | $56.31M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $15.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $27.80M derived: sum of 2 quarters · filed 2021-03-04 | $40.35M derived: sum of 3 quarters · filed 2021-03-04 | $51.20M 10-K · filed 2021-03-04 | $53.76M 10-K · filed 2020-03-03 | |||
| 2019-09-30 | $12.45M 10-Q · filed 2020-11-05 | $12.62M 10-Q · filed 2019-10-31 | $25.01M derived: sum of 2 quarters · filed 2020-11-05 | $35.86M 10-Q · filed 2020-11-05 | $42.00M 10-Q · filed 2019-10-31 | $62.42M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-06-30 | $12.56M 10-Q · filed 2020-08-06 | $13.46M 10-Q · filed 2019-08-01 | $23.40M 10-Q · filed 2020-08-06 | $29.38M 10-Q · filed 2019-08-01 | $49.97M derived: sum of 3 quarters · filed 2021-03-04 | $60.63M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-03-31 | $10.85M 10-Q · filed 2020-05-11 | $15.92M 10-Q · filed 2019-05-02 | $37.41M derived: sum of 2 quarters · filed 2021-03-04 | $48.08M derived: sum of 3 quarters · filed 2021-03-04 | $64.30M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | $26.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $37.23M derived: sum of 2 quarters · filed 2021-03-04 | $53.45M derived: sum of 3 quarters · filed 2021-03-04 | $64.47M 10-K · filed 2021-03-04 | $52.99M 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $10.67M 10-Q · filed 2019-10-31 | $26.89M derived: sum of 2 quarters · filed 2019-10-31 | $37.91M 10-Q · filed 2019-10-31 | $48.46M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-06-30 | $16.23M 10-Q · filed 2019-08-01 | $27.25M 10-Q · filed 2019-08-01 | $37.79M derived: sum of 3 quarters · filed 2020-03-03 | $45.80M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-03-31 | $11.02M 10-Q · filed 2019-05-02 | $21.57M derived: sum of 2 quarters · filed 2020-03-03 | $29.57M derived: sum of 3 quarters · filed 2020-03-03 | $35.03M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2017-12-31 | $10.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $18.55M derived: sum of 2 quarters · filed 2020-03-03 | $24.01M derived: sum of 3 quarters · filed 2020-03-03 | $29.01M 10-K · filed 2020-03-03 | ||||
| 2017-09-30 | $8.01M 10-Q · filed 2018-11-07 | $13.47M derived: sum of 2 quarters · filed 2018-11-07 | $18.46M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $5.46M 10-Q · filed 2018-08-01 | $10.45M 10-Q · filed 2018-08-01 | ||||||
| 2017-03-31 | $4.99M 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | $11.26M 10-K · filed 2019-02-28 | |||||||
| 2015-12-31 | $2.92M 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |